{"id":"W2946486395","doi":"10.1016/s1470-2045(19)30091-9","title":"Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Open label; Medicine; Internal medicine; Oncology; Lymphoma; Brentuximab vedotin; Phases of clinical research; Diffuse large B-cell lymphoma; Clinical trial; Hodgkin lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001500247,0.001459384,0.002703515,0.0004551213,0.0003445257,0.001376463,0.0007341169,0.001330079,0.003570526],"category_scores_gemma":[0.001226495,0.0006802094,0.001847009,0.0005205872,0.00141683,0.001520792,0.000410317,0.002758782,0.0008616868],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009659841,"about_ca_system_score_gemma":0.0007821819,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008911102,"about_ca_topic_score_gemma":0.00167964,"domain_scores_codex":[0.9992999,0.0003651882,0.00003097434,0.0001158303,0.00005743746,0.0001306583],"domain_scores_gemma":[0.99925,0.0002321292,0.0001491668,0.0000717404,0.00003848456,0.0002584701],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9453376,0.01055984,0.001781253,0.0006191278,0.001441158,0.00007819936,0.0001009043,0.0007257048,0.004667236,0.0001461593,0.0007346448,0.03380827],"study_design_scores_gemma":[0.8126339,0.178346,0.005537906,0.00004292755,0.0006025816,0.0001032973,0.00005073536,0.0005708187,0.0004753373,0.0002062211,0.001402143,0.00002813443],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992202,0.004307061,0.0004095088,0.0003936118,0.0002946505,0.0006372514,0.0003895428,0.00004520754,0.001321119],"genre_scores_gemma":[0.9915217,0.002822116,0.0007172885,0.0006951105,0.0003230404,0.0008420119,0.0008409527,0.00002177139,0.002215986],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003570526,"threshold_uncertainty_score":0.01194459,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01880862093623526,"score_gpt":0.3208220799402624,"score_spread":0.3020134590040272,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}